27es JNI 2026 PARIS
et la région Île-de-France Palais des Congrès
Journées Nationales d'infectiologie
du jeudi 18 juin au samedi 20 juin 2026
Journée Nationale de Formation des Paramédicaux en Infectiologie
Vendredi 19 juin 2026

Transmission sexuelle de la résistance bactérienne

Session « Nouvelles IST » en partenariat avec la Société Française de Dermatologie

Dr Laure Surgers
Sorbonne Université
Service des maladies infectieuses et tropicales, Hôpital Saint-Antoine
laure.surgers@aphp.fr

Déclaration d'intérêt de 2014 à 2025

- Intérêts financiers : 0
- Liens durables ou permanents : 0
- Interventions ponctuelles : 0
- Intérêts indirects : 0

Années 2000 : (ré)-émergence d'IST

CDC | CDC Home | Search | Health Topics A-Z

MMWR

Weekly

October 26, 2001 / 50(42);922-6

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.

Shigella sonnei Outbreak Among Men Who Have Sex with Men --- San Francisco, California, 2000--2001

Int J STD AIDS. 2004 Aug;15(8):533-7. doi: 10.1258/0956462041558221.

Shigellosis - a re-emerging sexually transmitted infection: outbreak in men having sex with men in Berlin

U Marcus [1], P Zucs, V Bremer, O Hamouda, R Prager, H Tschaepe, U Futh, M Kramer

Affiliations + expand

PMID: 15307964 DOI: 10.1258/0956462041558221

DOI: 10.1111/hiv.12191

HIV Medicine (2015), **16**, 168–175

ORIGINAL RESEARCH

Shigella flexneri serotype 1 infections in men who have sex with men in Vancouver, Canada

A Wilmer,[1] MG Romney,[1,2] R Gustafson,[3] J Sandhu,[4] T Chu,[4] C Ng,[5] L Hoang,[1,5] S Champagne[1,2] and MW Hull[6,7]

[1]*Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada,* [2]*Department of Pathology & Laboratory Medicine, Division of Medical Microbiology, St. Paul's Hospital, Vancouver, BC, Canada,* [3]*Communicable Disease Control, Vancouver Coastal Health, Vancouver, BC, Canada,* [4]*Public Health Surveillance Unit, Vancouver Coastal Health, Vancouver, BC, Canada,* [5]*British Columbia Centre for Disease Control, Public Health Microbiology & Reference Laboratory, Division of Mycology and Bacteriology, Vancouver, BC, Canada,* [6]*Department of Medicine, University of British Columbia, Vancouver, BC, Canada and* [7]*BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada*

IST classiques => nouvelles IST

Chlamydia trachomatis
Any site
Genital
Anorectal
Oropharyngeal
Neisseria gonorrhoeae
Any site
Genital
Anorectal
Oropharyngeal
Treponema pallidum [a]
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Mycoplasma genitalium
Trichomonas vaginalis

VIH

HPV
HSV

+ STEntericl

- *Shigella*
- *Salmonella*
- *Campylobacter*
- *Entamoeba*
- *Giardia…*

- Méningo C
- Zika
- Ebola
- Lassa…

+ Cutanée

- Gale
- Dermatophyte
- Folliculite à *K. aerogenes*
- Mpox
- *Staphylococcus aureus* (MR)…

+ multirésistance antibiotique ?????

To be continued…

Résistance antibiotique = problème santé publique





2050 = 10 millions de morts

Pays à ressources limitées ++

O'Neill. 2014-2016

Shigella XDR et HSH

CDC Centers for Disease Control and Prevention
CDC 24/7: Saving Lives, Protecting People™

EMERGING INFECTIOUS DISEASES®

EID Journal > Volume 20 > Number 5—May 2014 > Main Article

Volume 20, Number 5—May 2014

Dispatch

Shigella spp. with Reduced Azithromycin Susceptibility, Quebec, Canada, 2012–2013

Christiane Gaudreau, Sapha Barkati, Jean-Michel Leduc, Pierre A. Pilon, Julie Favreau, and Sadjia Bekal
Author affiliations: Centre Hospitalier de l'Université de Montréal–Hôpital Saint-Luc, Montreal, Quebec, Canada (C. Gaudreau, S. Barkati, J.-M. Leduc, J. Favreau); Université de Montréal, Montreal (C. Gaudreau, S. Barkati, J.-M. Leduc, P.A. Pilon, S. Bekal); Agence de la Santé et des Services Sociaux de Montréal-Santé Publique, Montreal (P.A. Pilon); Laboratoire de Santé Publique du Québec/Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Quebec, Canada (C. Gaudreau, S. Bekal)

Infection. 2013 Oct;41(5):999-1003. doi: 10.1007/s15010-013-0501-4. Epub 2013 Jul 13.

High rates of quinolone-resistant strains of Shigella sonnei in HIV-infected MSM

C Hoffmann [1], H Sahly, A Jessen, P Ingiliz, H-J Stellbrink, S Neifer, K Schewe, S Dupke, A Baumgarten, A Kuschel, I Krznaric

Affiliations + expand

PMID: 23852945 DOI: 10.1007/s15010-013-0501-4

Emergence of extensively drug-resistant and multidrug-resistant *Shigella flexneri* serotype 2a associated with sexual transmission among gay, bisexual, and other men who have sex with men, in England: a descriptive epidemiological study

Katie Thorley, Hannah Charles, David R Greig, Mateo Prochazka, Lewis C E Mason, Kate S Baker, Gauri Godbole, Katy Sinka, Claire Jenkins

Escherichia coli producteur de β lactamase à spectre étendu

The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance

Hatim Sati, Elena Carrara*, Alessia Savoldi, Paul Hansen, Jacopo Garlasco, Enrica Campagnaro, Simone Boccia, Juan Antonio Castillo-Polo, Eugenia Magrini, Pilar Garcia-Vello, Eve Wool, Valeria Gigante, Erin Duffy, Alessandro Cassini, Benedikt Huttner, Pilar Ramon Pardo, Mohsen Naghavi, Fuad Mirzayev, Matteo Zignol, Alexandra Cameron, Evelina Tacconelli, and the WHO Bacterial Priority Pathogens List Advisory Group†*

***Lancet Infect Dis* 2025; 25: 1033–43**

Published Online
April 14, 2025
https://doi.org/10.1016/S1473-3099(25)00118-5



Figure 2: **Final ranking of antibiotic-resistant bacteria in the 2024 WHO BPPL**

Transmission communautaire Ec BLSE



Beaumont et al. CMR 2026

Transmission sexuelle de Ec BLSE ?

- Etude BMR-IST
- Cohorte 2018-2019
- Monocentrique
- Population > 18 ans
- Sexuellement active



Prévalence colonisation Ec BLSE = 10 %

Surgers et al. CID 2022

BMR-IST : population

Characteristic	251 PrEP MSM	487 MSM	500 HIV MSM	439 MSW	480 WSM	*P* Value[b]
	Participants, No. (%)[a]					
Demographic characteristics						
Age, median (IQR), y	36 (29–45)	31 (25–40)	46	27 (23–33)	25	<.001
Geographic origin						<.001
Europe	200 (79.7)	395 (81.1)	399 (79.8)	348 (79.3)	393 (82.1)	
North America, DOM, TOM, or Australia	19 (7.6)	45 (9.2)	58 (11.6)	23 (5.2)	33 (6.9)	
Africa or Middle East	23 (9.2)	37 (7.6)	36 (7.2)	64 (14.6)	46 (9.6)	
Asia	9 (3.6)	10 (2.1)	7 (1.4)	4 (0.9)	7 (1.5)	
Born outside France	58 (21.1)	118 (24.2)	115 (23.0)	87 (19.8)	86 (17.9)	.11
Time since arrival in France, median (IQR), y[c]	9 (3–19)	7 (2–18)	16 (7–29)	4 (1–19)	4 (1–15)	<.001
Employment status						<.001
Employed	216 (86.1)	370 (76.0)	433 (86.6)	267 (60.8)	218 (45.4)	
Vegetarian or vegan diet	2 (4.2)	6 (6.5)	6 (4.0)	8 (9.5)	23 (16.2)	.005
Hospitalization in past 12 mo		18 (3.7)	41 (8.2)		20 (4.2)	.001
Antibiotic use in past 6 mo	37	122 (25.1)	149 (29.8)	10	75 (15.6)	<.001
Type of antibiotic used[f]						<.001
None	157 (62.6)	365 (75.0)	351 (70.2)	393 (89.5)	405 (84.4)	
β-Lactamines	30 (12.0)	59 (12.1)	62 (12.4)	28 (6.4)	47 (9.8)	
Doxycline	19 (7.6)	21 (4.3)	27 (5.4)		7 (1.5)	
Other		42 (8.6)	60 (12.0)	6	21 (4.4)	
Antibiotic use in past 3 mo	23	80 (16.4)	97 (19.4)		57 (11.9)	<.001
Travel outside France	190 (75.7)	383 (78.6)	335 (67.0)	313 (71.3)	358 (74.6)	.001

BMR-IST : prévalence de colonisation



Ajusté ATB
Ajusté Voyage

Sexual Group	Participants, No.	ESBL-E Positive, No. (%)	Univariable Analysis OR (95% CI)	*P* Value	Model 1[a] aOR (95% CI)	*P* Value	Model 2[b] aOR (95% CI)	*P* Value
HIV-negative MSM on PrEP	251		64 (1.63–4.30)	<.001			1.94 (1.09–3.44)	.02
HIV-negative MSM not on PrEP	487		45 (.91–2.30)	.12			1.19 (.72–1.97)	.51
HIV-positive MSM	500	61 (12.2)	1.88 (1.21–2.93)	.005	1.96 (1.17–3.28)	.01	1.75 (1.03–2.97)	.04
HIV-negative MSW	439		51 (.94–2.42)	.09	1.50 (.93–2.42)	.09	1.48 (.92–2.38)	.11
HIV-negative WSM	480		Reference	…	Reference	…	Reference	…

PrEP = 16 %

RR = 2,58

WSM = 6 %

Association Between Sexual Groups and Extended-Spectrum β-Lactamase–Producing Enterobacterales Carriage

Prévalence de colonisation uniforme ?

HSH



Prévalence de colonisation à Ec BLSE

Latent class[a]	*n*	Mean proportion of behaviors	ESBL-E prevalence
MSM (*N* = 1211)			
Class 1	259	29.9%	
Class 2	102	42.3%	12.7%
Class 3	124	44.8%	15.3%
Class 4	100	60.0%	16.0%
Class 5	198	62.2%	10.6%
Class 6	358	79.7%	
Class 7	70	91.7%	

7 %

24 %

PrEP/chemsex

Boyd et al. 2025

Stabilité de la colonisation à Ec BLSE ?

Microbiote chez 176 patients BLSE + vs BLSE –
16S rRNA gene amplicon

α diversité
Shannon Diversity Index



β diversité
NMDS analysis



Composition, α et β diversités identiques chez porteurs et non porteurs de Ec BLSE

Stabilité indépendante du microbiote

Boyd et al. 2025

BMR-IST : clones et enzymes de Ec BLSE

Variable	251 PrEP MSM	487 MSM	500 HIV MSM	439 MSW	480 WSM	*P* Value[b]
ST	(n = 46)	(n = 49)	(n = 72)	(n = 47)	(n = 37)	.001
ST10	3 (5.6)	1 (2.0)	8 (11.1)	1 (2.1)	2 (5.4)	
ST14	11 (23.9)	9 (18.4)	7 (9.7)	0 (0)	0 (0)	
ST131	8 (17.4)	14 (28.6)	14 (19.4)	12 (25.5)	13 (35.1)	
ST1193	6 (13.0)	5 (10.2)	9 (12.5)	1 (2.1)	2 (5.4)	
Other ST	18 (39.1)	20 (40.8)	34 (47.2)	33 (70.2)	20 (54.1)	
ESBL gene	(n = 46)	(n = 49)	(n = 72)	(n = 47)	(n = 37)	.004
CTX-M-15	22 (47.8)	27 (55.1)	45 (62.5)	29 (61.7)	21 (56.8)	
CTX-M-27	9 (19.6)	7 (14.3)	12 (16.7)	8 (17.0)	7 (18.9)	
SHV-12	11 (23.9)	10 (20.4)	8 (11.1)	0 (0)	0 (0)	
Other	4 (8.7)	5 (10.2)	7 (9.7)	10 (21.3)	9 (24.3)	

Ec BLSE complex clonal 14

ST14 *E. coli* core-genome phylogeny



ST1193 *E. coli* core-genome phylogeny



Vert clair : BMR-IST
Bleu : Enterobase

Danjean et al. Journal of infection 2025

Ec BLSE complex clonal 14

ST14
9 allelic variant differences
(median=3, [IQR=2-5])



ST131
0 to 700 allelic variant differences
(median=61, [IQR=45-675])



- Ec BLSE CC14 a émergé et disséminé chez HSH
- Association avec comportements sexuels (fisting)

Danjean et al. Journal of infection 2025

Transmission sexuelle de Ec BLSE = IST

- Sélection et dissémination de clones multirésistants à succès (CC14) : prises itératives d'antibiotiques chez patients IST +
- Associations à des pratiques sexuelles
- Clones à succès implantés indépendamment du microbiote

- Prévention ?
- Persistance ?
- Infection ?

Colonisation à Ec BLSE… plus récemment



32 %

> 36 %

HSH sous PrEP

Molina et al. 2024

Transmission sexuelle Ec BLSE (mais pas que)

Outbreak of sexually transmitted, extensively drug-resistant *Shigella sonnei* in the UK, 2021–22: a descriptive epidemiological study

Hannah Charles, Mateo Prochazka, Katie Thorley, Adam Crewdson, David R Greig, Claire Jenkins, Anais Painset, Helen Fifer, L
Paul Cabrey, Robert Smith, Daniel Richardson, Laura Waters, Katy Sinka, Gauri Godbole, on behalf of the Outbreak Control T

Clinical Infectious Diseases
MAJOR ARTICLE

International Spread of Multidrug-Resistant *Campylobacter coli* in Men Who Have Sex With Men in Washington State and Québec, 2015–2018

Alexander L. Greninger,[1,a] Amin Addetia,[1,a] Kimberly Starr,[1] Robert J. Cybulski,[2] Mary K. Stewart,[1] Stephen J. Salipante,[1] Andrew B. Bryan,[1] Brad Cookson,[1] Christiane Gaudreau,[3,4] Sadjia Bekal,[4,5] and Ferric C. Fang[1]

Review > Clin Microbiol Rev. 2025 Dec 11;38(4):e0007523. doi: 10.1128/cmr.00075-23.
Epub 2025 Sep 17.

Sexually transmitted enteric infections in men who have sex with men

Kira L Newman # 1, Gretchen Snoeyenbos Newman # 2, Chase A Cannon 3, Ferric C Fang 4

Conclusion, merci et bonne soirée à toutes et à tous

« Les personnes irréfléchies qui abuseront de la pénicilline seront moralement responsables de la mort des patients qui succomberont aux germes résistants, j'espère que ce fléau pourra être évité »

Alexander Fleming 1945
Discours de remise du Prix Nobel